The whole body absorbed dose of the patient administered 57Co-Bleomycin for tumor diagnosis was estimated in accordance with the MIRD Committee method.
The whole body retention function was well described by the two component exponential model.
The effective half-lives were several hours in the initial rapidly decreasing phase and 2-3 months in the successive slow phase. The accumulated whole body absorbed dose following intravenous administration of 1mCi of 57Co-Bleomycin was calculated to be approximately 3 rads, more than 90% of which was delivered in the first one year following injection.
It was also revealed that no less than 99% of the dose was brought by the slow phase component, which indicated the importance of obtaining slow phase excretion date for dose estimation concerning the newly applied radiosubstances, irrespective of necessity or unneeessity for the diagnosis itself. Relatively high level of deposition was observed in the liver of a male patient of 82 years old who died of lung cancer 15 days after intravenous injection of 57Co-Bleomycin. Table 1 from 100%, since the fecal excretion following the intravenous injection is known to be unimportanta. •¬ (1) where f1, f2: fractions of the rapid and slow phases, T1, T2: effective half-lives of the rapid and slow phases. The average whole body absorbed dose D (v) (rads) delivered by q(mCi) of 57Co-Bleomycin during z days following administration can be calculated by the next formula: is never too little to be safely neglected.
As to the cases C-G, the number of excretion data is not sufficient to allow the exact estimation of the slow phase halflives. If the excretion rate in the long-life component is nearly the same as those in the cases A and B, then the whole body absorbed dose for these patients also prove to be around 2 rails. energy absorbed per disintergration in the liver in case that 57Co is homogeneously distributed in the organ (=0.043 MeV).
If Teff for liver can pertinently be assumed to be as long as that for the total body (viz., Teff=60-90 days), the accumulated absorbed dose DL will ultimately amount to almost 7-10 rails.
Discussions
The values of effective half-lives estimated in the present study from only eightday excretion data are inevitably accompanied with a certain error. The 95% confidential limit of T2 for the case B, for example, was estimated to be 70-110 days.
The longer term observation must be carried out for more accurate evaluation.
In the present investigation, the fecal excretion was not traced, and therefore the absorbed dose here calculated is rather an overestimation to some extent. 
Conclusion
The whole body absorbed dose of the patient administered 57Co-Bleomycin for tumor diagnosis was estimated.
The whole body retention function was well described by the two component exponential model, the effective half-lives of which were several hours in the rapidly decreasing phase and 2-3 months in the slow phase. Intravenous injection of 1 mCi of 57Co-Bleomycin proved to deliver 2-3 rads to the total body. Relatively high level of deposition was observed in the liver of a male patient of 82 years old who died of lung cancer 15 days after intravenous injection of 57Co-Bleomycin.
